BSE · 524592 · Chemicals
Jaysynth Orgochem Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹59 Cr with net profit ₹5 Cr — a 9.1% net margin, versus 7.92% the period before.
Shareholding
As of 2026-06-30
- Promoter73.68%
- Public26.3%
- FII0.01%
- DII0.01%
15,482 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.3× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Dyes And Pigments · ranked #14 of 28 by market cap · medians across 20 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sudarshan Chemical Industries Ltd. | ₹10,118 Cr | 99.75 | 2.87 | 0.36% | 0.73% |
| Kiri Industries Limited | ₹3,409 Cr | 4.24 | 0.51 | -1.55% | 615.5% |
| Bodal Chemicals Ltd. | ₹2,092 Cr | 30.42 | 1.81 | 4.13% | 3.03% |
| Indokem Ltd. | ₹1,730 Cr | 775.56 | 36.72 | 2.9% | 1.28% |
| Vidhi Specialty Food Ingredients Ltd. | ₹1,693 Cr | 31.79 | 5.18 | 14.93% | 12.15% |
| Shree Pushkar Chemicals & Fertilizers Ltd. | ₹1,590 Cr | 22.05 | 2.62 | 11.49% | 7.19% |
| Bhageria Industries Ltd. | ₹1,323 Cr | 19.18 | 2.22 | 7.72% | 6.88% |
| Ultramarine & Pigments Limited | ₹1,265 Cr | 14.02 | 1.46 | 9.29% | 11.1% |
| Vipul Organics Limited | ₹517 Cr | 63.28 | 4.41 | 5.9% | 4.31% |
| Asahi Songwon Color Ltd. | ₹443 Cr | 12.71 | 1.65 | 6.92% | 6.06% |
| Jaysynth Orgochem Limited(this company) | ₹225 Cr | 12.15 | 1.65 | 10.96% | 7.13% |
AI analysis
AI-generated · google/gemini-2.5-flashJaysynth Orgochem Limited has a market capitalization of Rs 163 Cr. The company reported revenue of Rs 231.47 Cr and a profit margin of 5.65%. Earnings per share stand at Rs 1.09, with a return on equity of 10.96% and a return on capital employed of 12.43%. The company's 52-week high was Rs 24.7 and its low was Rs 9.57.
Positives
- +The debt-to-equity ratio is low at 0.03, indicating minimal financial leverage.
- +Promoter shareholding is substantial at 73.68% as of March 31, 2026.
- +No promoter shares are reported as pledged (0%).
Negatives
- −The dividend yield is high at 41%, which might warrant further investigation into its sustainability.
- −The company's revenue growth is not available in the provided data.
- −Quarterly net profit decreased from Rs 5.46 Cr in Dec 2024 to Rs 2.33 Cr in Dec 2025, representing a decline of 57.32%.
Financial Performance
In the latest annual reporting period (Mar 2026), Jaysynth Orgochem Limited reported revenue of Rs 66.93 Cr and a net profit of Rs 5.3 Cr. Over the last four reported quarters, revenue has fluctuated, with the highest being Rs 69.46 Cr in Mar 2026 and the lowest at Rs 59.01 Cr in Jun 2025. Net profit also varied, reaching Rs 5.66 Cr in Mar 2026 and Rs 1.72 Cr in Jun 2025.
Profitability & Returns
Jaysynth Orgochem Limited achieved a profit margin of 5.65%. The company's return on equity (ROE) is 10.96% and return on capital employed (ROCE) is 12.43%. Earnings per share (EPS) for the company are Rs 1.09. EBITDA for the latest annual reporting period (Mar 2026) was Rs 8.07 Cr.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.03. The book value per share is Rs 9.91. This indicates a relatively healthy financial structure with minimal leverage.
Ownership & Pledges
Institutional holdings collectively amount to 0.01%. There are no pledged shares reported by the promoters.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.